Fernández Cecilia A, Moses Marsha A
Vascular Biology Program and Department of Surgery, Children's Hospital Boston and Department of Surgery, Harvard Medical School, Boston, MA 02115, USA.
Biochem Biophys Res Commun. 2006 Jun 23;345(1):523-9. doi: 10.1016/j.bbrc.2006.04.083. Epub 2006 Apr 27.
Despite the importance of MMP activity in the regulation of angiogenesis, relatively little is known about the role of TIMP-4, the most recently discovered endogenous MMP inhibitor, in modulating neovascularization. It has largely been assumed that all TIMPs are capable of inhibiting angiogenesis in vivo. However, it is now widely appreciated that TIMPs-1, -2, and -3 differ significantly in their ability to modulate angiogenic processes in vitro and angiogenesis in vivo. In order to study the effect of TIMP-4 in controlling angiogenesis, we have cloned and expressed TIMP-4 in a Pichia pastoris expression system, purified it to homogeneity, and tested its ability to regulate angiogenesis in vivo and in vitro. Our studies demonstrate that TIMP-4 is an inhibitor of capillary endothelial cell migration, but not of proliferation or of angiogenesis in vivo.
尽管基质金属蛋白酶(MMP)活性在血管生成调节中具有重要作用,但对于最近发现的内源性MMP抑制剂金属蛋白酶组织抑制因子-4(TIMP-4)在调节新血管形成中的作用,人们了解相对较少。过去大多认为所有的TIMP都能够在体内抑制血管生成。然而,现在人们普遍认识到,TIMP-1、-2和-3在体外调节血管生成过程以及在体内调节血管生成的能力上存在显著差异。为了研究TIMP-4在控制血管生成中的作用,我们在毕赤酵母表达系统中克隆并表达了TIMP-4,将其纯化至同质,并测试了其在体内和体外调节血管生成的能力。我们的研究表明,TIMP-4是毛细血管内皮细胞迁移的抑制剂,但不是体内细胞增殖或血管生成的抑制剂。